Your session is about to expire
← Back to Search
Sequential Therapy for Multiple Myeloma (MASTER Trial)
MASTER Trial Summary
This trial is testing a new treatment regimen for MM that may be more effective than current treatments.
- Multiple Myeloma
MASTER Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMASTER Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 123 Patients • NCT03224507MASTER Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are allergic to Captisol, which is a substance used to dissolve carfilzomib.You have had fluid drained from around your lungs or abdomen in the past 3 weeks.You must be at least 18 years old with no maximum age limit.You have been diagnosed with certain specific blood-related conditions.Your lung function is less than half of what is expected for someone your age and size.You haven't received any specific treatment for your condition, except for certain medications used to manage symptoms, for up to four weeks before joining the study. If you did receive treatment, we need to have certain test results to understand your condition.You have a certain amount of abnormal proteins in your blood or urine.You are expected to live for at least 12 months.You have had a heart attack or unstable angina in the last 4 months, or you have severe heart problems that are not well controlled.You are able to carry out daily activities without any major issues.You have been recently diagnosed with multiple myeloma and need to start treatment.You have HIV.You have an ongoing hepatitis B or C infection.Your liver is working well, with specific levels of ALT and bilirubin within a certain range.Your kidneys are working well, with a clearance of creatinine greater than 40 mL per minute, as measured by a test or calculated using a standard formula.You have had a stroke or mini-stroke (TIA) in the past year.You had cancer, except for certain types that were treated and are unlikely to affect your health during the study.You have severe nerve damage or moderate nerve damage with pain within the past 21 days.You cannot take Aspirin or Acyclovir because they cause a bad reaction or are not safe for you.
- Group 1: KRdD followed by auto-HCT
- Group 2: KRdD only
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How widely is the survey being conducted across North America?
"This research study is recruiting patients from 4 medical facilities, such as Oregon Health and Science University in Portland, University of Wisconsin's School of Medicine and Public Health in Madison, Vanderbilt Ingram Cancer Center in Nashville, plus four additional sites."
What is the current enrolment limit for this research project?
"At this time, no new patients are being recruited for the study that was first advertised on March 14th 2018 and last edited September 12th 2022. However, if you're looking for alternative studies, 807 trials related to multiple myeloma and 751 investigations concerning KRdD plus auto-HCT are actively seeking participants."
Could you provide a synopsis of findings from prior research regarding KRdD and subsequent auto-HCT?
"The KRdD procedure followed by an autologous hematopoietic stem cell transplantation was first trialled in 2002 at Manitoba Blood & Marrow Transplant Program CancerCare Manitoba. Since then, 1391 trials have been completed, with 751 presently active clinical studies - many of which are conducted out of Portland, Oregon."
What type of ailment is the KRdD and auto-HCT treatment regimen typically used to target?
"Ophthalmologic sympathetic ophthalmia typically calls for KRdD and auto-HCT as the treatment of choice. Additionally, this twofold approach has been shown to be helpful in managing a range of other health issues such as post-chemotherapy complications, branch retinal vein occlusion, and macular edema."
Has the Food and Drug Administration greenlighted KRdD preceding autologous hematopoietic cell transplantation?
"After carefully assessing the data available, our team at Power has assigned KRdD followed by auto-HCT a rating of 2 on the safety scale. Since this is only in Phase 2, there are limited confirmations of its efficacy and some evidence to suggest it may be safe."
Is this experiment presently procuring participants?
"This research endeavour has closed its doors to new patients, as the last edit date was September 12th 2022. However, if you are looking for other trials that might suit your needs, there are currently 807 clinical studies inviting people with multiple myeloma and 751 similar efforts recruiting those suffering from KRdD in combination with auto-HCT."
Share this study with friends
Copy Link
Messenger